Table 1 Patient and tumor characteristics according to statin use.

From: Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study

All n = 910

Factor

Pre-diagnostic statin

n ≤ 74 n (%) or

mean (min–max)

Post-diagnostic statin

n ≤ 238

n (%) or mean (min–max)

Any statin

n ≤ 312

n (%) or mean (min–max)

Never statin

n ≤ 598

n (%) or mean (min–max)

P-value

any vs

never statin use

Age at baseline (n = 910)

56.4 (44.7–73.0)

56.4 (46.8–71.5)

57.2 (44.9–72.8)

57.0 (44.9–72.8)

56.2 (44.7–73.0)

0.10a)

Age at diagnosis (n = 910)

65.5 (45.7–87.3)

71.1 (59.6–85.6)

64.9 (48.4–84.7)

66.3 (48.4–85.6)

65.0 (45.7–87.3)

0.02a)∗

BMI at baseline (n = 910)

<25

466 (51)

29 (39)

98 (41)

127 (41)

339 (57)

 

≥25 and <30

310 (34)

29 (39)

91 (38)

120 (38)

190 (32)

 

≥30

134 (15)

16 (22)

49 (21)

65 (21)

69 (11)

<0.01b)∗

Tumor size (n = 887)

≤20 mm

637 (72)

51 (72)

178 (76)

229 (75)

408 (70)

 

>20 mm

250 (28)

20 (28)

57 (24)

77 (25)

173 (30)

0.15

ALNI (n = 819)

Positive (≥1 metastatic node)

262 (32)

23 (33)

65 (30)

88 (31)

174 (33)

 

Negative

557 (68)

47 (67)

151 (70)

198 (69)

359 (67)

0.58

NHG (n = 835)

I

227 (27)

12 (17)

63 (28)

75 (26)

152 (28)

 

II

392 (47)

32 (46)

112 (51)

144 (49)

248 (46)

 

III

216 (26)

26 (37)

47 (21)

73 (25)

143 (26)

0.85b)

ER status (n = 760)

Positive (>10%)

671 (88)

58 (87)

183 (89)

241 (89)

430 (88)

 

Negative (≤10%)

89 (12)

9 (13)

22 (11)

31 (11)

58 (12)

0.84

PR status (n = 689)

Positive (>10%)

378 (55)

49 (77)

106 (57)

155 (62)

223 (51)

 

Negative (≤10%)

311 (45)

15 (23)

81 (43)

96 (38)

215 (49)

0.01∗

HER2 status (n = 593)

Positive

52 (9)

6 (15)

14 (8)

20 (10)

32 (8)

 

Negative

541 (91)

33 (85)

158 (92)

191 (90)

350 (92)

0.65

Ki67 (n = 633)

Low (≤10%)

419 (66)

17 (40)

138 (73)

155 (67)

264 (66)

 

High (>10%)

214 (34)

25 (60)

51 (27)

76 (33)

138 (34)

0.72

HMGCR expression (n = 657)

negative

119 (18)

5 (8)

33 (18)

38 (16)

83 (19)

 

weak

354 (54)

33 (52)

103 (58)

136 (56)

225 (52)

 

moderate/strong

184 (28)

26 (41)

42 (24)

68 (28)

121 (28)

0.43b)

  1. BMI: body mass index; ALNI: axillary lymph node involvement, NHG: Nottingham histological grade; ER: estrogen receptor, PR: progesterone receptor; HER2: Human epidermal growth factor 2; TNBC: triple negative breast cancer; HMGCR: HMG-CoA reductase; TAM: tamoxifen; AI: aromatase inhibitors. Pearson X2 test if not specified otherwise. a)Linear regression. b)Linear-by-Linear association. P-value between any statin treatment and never statin treatment. ∗P < 0.05. Pre-diagnostic statin use: statin prescribed before breast cancer diagnos. Post-diagnostic statin use: statin prescribed after breast cancer diagnos. Any statin use: patients prescribed statin at any point; either pre-diagnostic and/or post-diagnostic. Never statin use: patients never prescribed statin.
Back to article page